## SEC Form 4

 $\Box$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

1. Name and Address of Reporting Person <sup>*</sup> BOWMAN JACK L						2. Issuer Name and Ticker or Trading Symbol AVI BIOPHARMA INC [ AVII ]							(Che	elationship eck all appli C Directo	cable)	g Pers	on(s) to Is 10% O	
(Last) ONE SW	```	=irst) BIA, SUITE 110	3. Date of Earliest Transaction (Month/Day/Year) 03/25/2004								Officer below)	(give title		Other ( below)	specify			
ļ		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. In Line	6. Individual or Joint/Group Filing (Check Applicable								
(Street)	AND C	DR									2	Form f	iled by One iled by Mor	•	0			
(City)	(	State)	(Zip)											Persor	I			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) Date (Month/Date)						Execution Date,			tion 1str.	4. Securit Disposed 5)	ties / I Of (	Acquired (D) (Instr.	(A) or 3, 4 and	Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following Reported		nership : Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
				Cod	le	v	Amount (A) or (D)			Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of 2. 3. Transaction 3A. Deemed 4						5. Number	6. Date Exercisable and 7. Title and Am				Amount	8. Price of	9. Numbe	r of	10.	11. Nature		

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ve es d ed nstr.	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$3.02	03/25/2004		A		33,334		03/25/2005	03/25/2014	Common Stock	33,334	\$0	33,334	D	

Explanation of Responses:

## Jack Bowman

Date

03/30/2004

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.